Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Usana Health Sciences (USNA) over the last 15 years, with Q3 2025 value amounting to $3.6 million.

  • Usana Health Sciences' Share-based Compensation rose 95.99% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.7 million, marking a year-over-year decrease of 614.89%. This contributed to the annual value of $14.6 million for FY2024, which is 25.35% down from last year.
  • According to the latest figures from Q3 2025, Usana Health Sciences' Share-based Compensation is $3.6 million, which was up 95.99% from $3.6 million recorded in Q2 2025.
  • Over the past 5 years, Usana Health Sciences' Share-based Compensation peaked at $3.8 million during Q1 2022, and registered a low of $2.9 million during Q1 2025.
  • Its 5-year average for Share-based Compensation is $3.5 million, with a median of $3.6 million in 2024.
  • As far as peak fluctuations go, Usana Health Sciences' Share-based Compensation skyrocketed by 1931.08% in 2023, and later crashed by 2150.45% in 2025.
  • Over the past 5 years, Usana Health Sciences' Share-based Compensation (Quarter) stood at $3.7 million in 2021, then decreased by 5.99% to $3.5 million in 2022, then grew by 3.61% to $3.6 million in 2023, then decreased by 0.82% to $3.6 million in 2024, then fell by 1.02% to $3.6 million in 2025.
  • Its Share-based Compensation stands at $3.6 million for Q3 2025, versus $3.6 million for Q2 2025 and $2.9 million for Q1 2025.